JANX007 is Janux’s lead novel Tumor Activated T Cell Engager (TRACTr). JANX007 is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of tumors and is in development for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Prostate cancer is the second most common cancer in men, leading to over 34,000 deaths in the United States annually. PSMA is known to be highly expressed in prostate cancer which has led to the development of PSMA-targeted biologics, including T cell engagers (TCEs). A third-party clinical trial with a continuously infused PSMA-TCE (no longer in development) demonstrated clinical benefit, suggesting the potential of a PSMA-TCE approach.
Given the challenges of continuous infusion, other companies are developing traditional TCEs that enable once-weekly or longer dosing. However, clinical trial results with these have shown dose-limiting cytokine release syndrome (CRS) toxicities as single agents, highlighting the limitations of unmasked traditional TCEs.